- Home
- AMAL vs SGP Comparison
AMAL vs SGP Comparison
Compare AMAL & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | SGP |
|---|---|---|
| Founded | 1923 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 932.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAL | SGP |
|---|---|---|
| Price | $41.34 | $21.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $36.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 106.7K | 51.9K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $49.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $20.15 |
| 52 Week High | $44.01 | $30.56 |
Technical Indicators
Market Signals| Indicator | AMAL | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 36.44 |
| Support Level | $36.50 | N/A |
| Resistance Level | $42.70 | $26.29 |
| Average True Range (ATR) | 1.09 | 1.54 |
| MACD | -0.03 | -0.28 |
| Stochastic Oscillator | 54.98 | 2.59 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.